elranatamab,daratumumab,PF-06863135,Lenalidomide
pfizer,janssen
['magnetismm-3', ' aca ', 'mmsm', 'elranatamab', '1921', ' gilt ']
congress | #ash22
nizar bahlis , presents phase ii magnetismm-3 trial of elranatamab in triple-class and penta-drug rrmm, na ve to bcma-targeted therapy. orr by bicr = 61%, with 84.4% patients achieving 9-month dor.
#mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma